Literature DB >> 19360406

2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells.

Bianca Altvater1, Silke Landmeier, Sibylle Pscherer, Jaane Temme, Heribert Juergens, Martin Pule, Claudia Rossig.   

Abstract

Regulatory NK cell receptors can contribute to antigen-specific adaptive immune responses by modulating T cell receptor (TCR)-induced T cell activation. We investigated the potential of the NK cell receptor 2B4 (CD244) to enhance tumor antigen-induced activation of human T cells. 2B4 is a member of the CD2 receptor subfamily with both activating and inhibitory functions in NK cells. In T cells, its expression is positively associated with the acquisition of a cytolytic effector memory phenotype. Recombinant chimeric receptors that link extracellular single-chain Fv fragments specific for the tumor-associated surface antigens CD19 and G(D2) to the signaling domains of human 2B4 and/or TCRzeta were expressed in non-specifically activated peripheral blood T cells by retroviral gene transfer. While 2B4 signaling alone failed to induce T cell effector functions or proliferation, it significantly augmented the antigen-specific activation responses induced by TCRzeta. 2B4 costimulation did not affect the predominant effector memory phenotype of expanding T cells, nor did it increase the proportion of T cells with regulatory phenotype (CD4+CD25(hi)FoxP3+). These data support a costimulatory role for 2B4 in human T cell subpopulations. As an amplifier of TCR-mediated signals, 2B4 may provide a powerful new tool for immunotherapy of cancer, promoting sustained activation and proliferation of gene-modified antitumor T cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19360406     DOI: 10.1007/s00262-009-0704-9

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  21 in total

1.  Selective Loss of Signaling Lymphocytic Activation Molecule Family Member 4-Positive CD8+ T Cells Contributes to the Decreased Cytotoxic Cell Activity in Systemic Lupus Erythematosus.

Authors:  Katalin Kis-Toth; Denis Comte; Maria P Karampetsou; Vasileios C Kyttaris; Lakshmi Kannan; Cox Terhorst; George C Tsokos
Journal:  Arthritis Rheumatol       Date:  2016-01       Impact factor: 10.995

Review 2.  Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.

Authors:  Marco Ruella; Carl H June
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

3.  Murine lung cancer induces generalized T-cell exhaustion.

Authors:  Rohit Mittal; Ching-Wen Chen; John D Lyons; Lindsay M Margoles; Zhe Liang; Craig M Coopersmith; Mandy L Ford
Journal:  J Surg Res       Date:  2015-02-12       Impact factor: 2.192

4.  2B4+ CD8+ T cells play an inhibitory role against constrained HIV epitopes.

Authors:  Kim N Aldy; Nathan C Horton; Porunelloor A Mathew; Stephen O Mathew
Journal:  Biochem Biophys Res Commun       Date:  2011-01-21       Impact factor: 3.575

Review 5.  Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors.

Authors:  Giovanni Fucà; Loic Reppel; Elisa Landoni; Barbara Savoldo; Gianpietro Dotti
Journal:  Clin Cancer Res       Date:  2020-02-03       Impact factor: 12.531

6.  Pseudomonas aeruginosa Infection Impairs NKG2D-Dependent NK Cell Cytotoxicity through Regulatory T-Cell Activation.

Authors:  Mickael Vourc'h; Gaelle David; Benjamin Gaborit; Alexis Broquet; Cedric Jacqueline; Tanguy Chaumette; Jocelyne Caillon; Antoine Roquilly; Christelle Retiere; Karim Asehnoune
Journal:  Infect Immun       Date:  2020-11-16       Impact factor: 3.441

7.  Strategies and developments of immunotherapies in osteosarcoma.

Authors:  Jia Wan; Xianghong Zhang; Tang Liu; Xiangsheng Zhang
Journal:  Oncol Lett       Date:  2015-11-24       Impact factor: 2.967

Review 8.  CAR T-cell immunotherapy: The path from the by-road to the freeway?

Authors:  Lynsey M Whilding; John Maher
Journal:  Mol Oncol       Date:  2015-10-23       Impact factor: 6.603

9.  Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells.

Authors:  John Maher
Journal:  ISRN Oncol       Date:  2012-12-09

10.  Evolving role of 2B4/CD244 in T and NK cell responses during virus infection.

Authors:  Stephen N Waggoner; Vinay Kumar
Journal:  Front Immunol       Date:  2012-12-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.